Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients

Phase 4

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Clozapine

• Registration Number: NCT01663077
• Lead Sponsor: Tirat Carmel Mental Health Center

Brief Summary

Approximately 30-60% of all schizophrenia patients who fail to respond to typical antipsychotics may respond to Clozapine. Clozapine has long been considered the "gold standard" within the atypical neuroleptic spectrum, backed by years of clinical experience and research, but uncertainties remain in some aspects of this drug. One such question is the link between dose, blood levels and patient clinical response. The Clozapine therapeutic plasma levels range between 250 - 450 ng/mL creating difficulties in using these results in routine clinical practice. Approximately 30% - 51% of "treatment-resistant schizophrenia" patients do not fully respond to Clozapine, a poorly understood phenomenon. Factors relevant to Clozapine-resistance include co-morbidity, drug misuse, poor adherence, inadequate duration of treatment and inadequate dose/plasma-levels. Pharmacogenetic factors such as different polymorphisms in involved genes may play a role. Pharmacodynamic and genetic data appear important in determining the clinical response to Clozapine. Clozapine-treated patients possessing different 3A4 polymorphisms, may respond differently as compared to other patients having normal 3A4 alleles. Recently, the CYP2D6 has also been involved in this drug metabolic pathway. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. This pharmacogenetic explanation/hypothesis may explain Clozapine- resistance in schizophrenics.

The high variability in plasma levels requires a large study in order to be able to determine correlation between clinical efficacy and plasma levels and genotyping. A preliminary study will enable power analysis and adequate determination of sample size.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-07-25
• Study First Submitted QC: 2012-08-08
• Study First Posted: 2012-08-13
• Study Start: 2012-10
• Primary Completion: 2016-11
• Study Completion: 2016-12
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-11
• Last Update Posted: 2017-10-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• DSM-IV criteria for schizophrenia (American Psychiatric Association 2000)
• All clozapine mono-therapy patients (only 300 mg/day) who respond to treatment and achieved symptomatic remission (45, 46) and were stable for at least 3 month will be included
• No change in benzodiazepine medications for the trial period.
• Legal ability and willingness to sign an informed consent form for participation in the study.

Exclusion Criteria

• Evidence of serious neurologic or endocrine disorder, for example severe head trauma, seizure disorder, dementia, Cushing's disease, thyroid disorder, mental retardation, alcohol or drug abuse, substance dependence (other than nicotine dependence), or presenting symptoms likely substance- induced, as judged by a study physician.
• Unstable medical illness or neurologic illness (seizures, CVA); breast, uterine, or ovarian cancer.
• Pregnant women, use of oral contraceptives or other hormonal supplementation such as estrogen. [Female patients will also have a pregnancy test.].

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Clozapine	Clozapine	Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month

Primary Outcome Measures

Name	Time	Method
Clozapine steady state plasma level	3 month

Secondary Outcome Measures

Name	Time	Method
Polymorphism of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in clinically stable schizophrenic adult patients	Once

Trial Locations

Locations (1)

Tirat Carmel Mental Health Center; 🇮🇱 Tirat Carmel, Israel